{"id":3548,"date":"2023-06-15T16:51:32","date_gmt":"2023-06-15T14:51:32","guid":{"rendered":"http:\/\/www.internalmed-journal.in.ua\/?p=3548"},"modified":"2023-08-11T13:42:35","modified_gmt":"2023-08-11T11:42:35","slug":"%d0%bd%d0%be%d0%b2%d1%96-%d0%bf%d1%96%d0%b4%d1%85%d0%be%d0%b4%d0%b8-%d0%b2-%d0%b4%d1%96%d0%b0%d0%b3%d0%bd%d0%be%d1%81%d1%82%d0%b8%d1%86%d1%96-%d1%82%d0%b0-%d0%bb%d1%96%d0%ba%d1%83%d0%b2%d0%b0%d0%bd","status":"publish","type":"post","link":"http:\/\/www.internalmed-journal.in.ua\/en\/archives\/3548","title":{"rendered":"New approaches in the diagnosis and treatment of non-alcoholic fatty liver disease"},"content":{"rendered":"

Prof<\/strong>. <\/strong>Sergienko<\/strong> O<\/strong>.<\/strong>I<\/strong>., <\/strong>prof<\/strong>. <\/strong>Oparin<\/strong> A<\/strong>.<\/strong>G<\/strong>., <\/strong>assoc<\/strong>. <\/strong>prof<\/strong>. <\/strong>Novokhatnya<\/strong> \u0410.<\/strong>E<\/strong>. \u00a0<\/strong><\/p>\n

Kharkiv National Medical University <\/strong><\/p>\n

Department of therapy \u21162 <\/strong><\/p>\n

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of liver diseases: 25% of the population of European countries have signs of NAFLD, 10\u201320% of patients with steatosis develop an inflammatory process (non-alcoholic steatohepatitis), which, if not treated, can transform into fibrosis and cirrhosis. In most people, NAFLD is not diagnosed, prognosis is inaccurate, and there are no licensed methods of treating the disease. In this review, we discuss some recent developments in NAFLD, focusing on disease definition, diagnosis, and treatment.<\/p>\n

Key words:<\/strong> non-alcoholic fatty liver disease, diagnostics, treatment.<\/p>\n

https:\/\/doi.org\/10.15407\/internalmed2023.02.012<\/strong><\/a><\/p>\n

Download.PDF (ukr)<\/strong><\/a><\/p>\n

Cite:<\/strong><\/p>\n

    \n
  1. \u0421\u0435\u0440\u0433\u0456\u0454\u043d\u043a\u043e, \u041e.\u0406. \u041d\u043e\u0432\u0456 \u043f\u0456\u0434\u0445\u043e\u0434\u0438 \u0432 \u0434\u0456\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u0446\u0456 \u0442\u0430 \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u0456 \u043d\u0435\u0430\u043b\u043a\u043e\u0433\u043e\u043b\u044c\u043d\u043e\u0457 \u0436\u0438\u0440\u043e\u0432\u043e\u0457 \u0445\u0432\u043e\u0440\u043e\u0431\u0438 \u043f\u0435\u0447\u0456\u043d\u043a\u0438 \/ \u041e.\u0406. \u0421\u0435\u0440\u0433\u0456\u0454\u043d\u043a\u043e, \u0410.\u0413. \u041e\u043f\u0430\u0440\u0456\u043d, \u0410.\u0404. \u041d\u043e\u0432\u043e\u0445\u0430\u0442\u043d\u044f \/\/ \u0421\u0445\u0456\u0434\u043d\u043e\u0454\u0432\u0440\u043e\u043f\u0435\u0439\u0441\u044c\u043a\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b \u0432\u043d\u0443\u0442\u0440\u0456\u0448\u043d\u044c\u043e\u0457 \u0442\u0430 \u0441\u0456\u043c\u0435\u0439\u043d\u043e\u0457 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0438. – 2023. – \u2116 2. – \u0421. 12-17. http:\/\/doi.org\/10.15407\/internalmed2023.02.012<\/li>\n
  2. Sergienko OI, Oparin AG, Novokhatnya \u0410E. [New approaches in the diagnosis and treatment of non-alcoholic fatty liver disease]. Shidnoevr. z. vnutr. simejnoi med. 2023;2:12-17. Ukrainian. http:\/\/doi.org\/10.15407\/internalmed2023.02.012<\/li>\n<\/ol>\n

    References:<\/strong><\/p>\n

      \n
    1. Spiers J, Brindley J, Li W, Alazawi W. What\u2019s new in non-alcoholic fatty liver disease?. Frontline Gastroenterology. 2022;13(e1):e102-e108. http:\/\/dx.doi.org\/10.1136\/flgastro-2022-102122<\/li>\n
    2. Alexander M, Loomis A, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Kendrick S, Waterworth D, Sattar N, Alazawi W. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Medicine. 2018;16(1):. http:\/\/dx.doi.org\/10.1186\/s12916-018-1103-x<\/li>\n
    3. Eslam M, Sanyal A, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, Kleiner D, Brunt E, Bugianesi E, Yki-J\u00e4rvinen H, Gr\u00f8nb\u00e6k H, Cortez-Pinto H, George J, Fan J, Valenti L, Abdelmalek M, Romero-Gomez M, Rinella M, Arrese M, Eslam M, Bedossa P, Newsome P, Anstee Q, Jalan R, Bataller R, Loomba R, Sookoian S, Sarin S, Harrison S, Kawaguchi T, Wong V, Ratziu V, Yilmaz Y, Younossi Z. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. http:\/\/dx.doi.org\/10.1053\/j.gastro.2019.11.312<\/li>\n
    4. Kim D, Konyn P, Sandhu K, Dennis B, Cheung A, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. Journal of Hepatology. 2021;75(6):1284-1291. http:\/\/dx.doi.org\/10.1016\/j.jhep.2021.07.035<\/li>\n
    5. Wagner R, Heni M, Tab\u00e1k A, Machann J, Schick F, Randrianarisoa E, Hrab\u011b de Angelis M, Birkenfeld A, Stefan N, Peter A, H\u00e4ring H, Fritsche A. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nature Medicine. 2021;27(1):49-57. http:\/\/dx.doi.org\/10.1038\/s41591-020-1116-9<\/li>\n
    6. Alexander M, Loomis A, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Dhalwani N, Kendrick S, Celis-Morales C, Waterworth D, Alazawi W, Sattar N. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019;:l5367. http:\/\/dx.doi.org\/10.1136\/bmj.l5367<\/li>\n
    7. Tan D, Ng C, Lin S, Pan X, Tay P, Lim W, Teng M, Syn N, Lim G, Yong J, Quek J, Xiao J, Dan Y, Siddiqui M, Sanyal A, Muthiah M, Loomba R, Huang D. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology. 2022;23(4):521-530. http:\/\/dx.doi.org\/10.1016\/s1470-2045(22)00078-x<\/li>\n
    8. Li W, Kadler B, Brindley J, Hood G, Devalia K, Loy J, Syn W, Alazawi W. The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population. Scientific Reports. 2022;12(1):. http:\/\/dx.doi.org\/10.1038\/s41598-022-08358-y<\/li>\n
    9. Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nature Reviews Gastroenterology &amp; Hepatology. 2019;17(1):40-52. http:\/\/dx.doi.org\/10.1038\/s41575-019-0212-0<\/li>\n
    10. Ataseven H, Yildirim M, Yalniz M. The value of ultrasonography and computerized tomography in estimating the histopathological severity of nonalcoholic steatohepatitis. Acta Gastroenterol. 2005;68(2):221-225.<\/li>\n
    11. Chen J, Yin M, Talwalkar J, Oudry J, Glaser K, Smyrk T, Miette V, Sandrin L, Ehman R. Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity. Radiology. 2017;283(2):418-428. http:\/\/dx.doi.org\/10.1148\/radiol.2016160685<\/li>\n
    12. Brunt E, Neuschwander-Tetri B, Oliver D, Wehmeier K, Bacon B. Nonalcoholic steatohepatitis: Histologic features and clinical correlations with 30 blinded biopsy specimens. Human Pathology. 2004;35(9):1070-1082. http:\/\/dx.doi.org\/10.1016\/j.humpath.2004.04.017<\/li>\n
    13. Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology. 2017;67(6):1265-1273. http:\/\/dx.doi.org\/10.1016\/j.jhep.2017.07.027<\/li>\n
    14. Davison B, Harrison S, Cotter G, Alkhouri N, Sanyal A, Edwards C, Colca J, Iwashita J, Koch G, Dittrich H. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. Journal of Hepatology. 2020;73(6):1322-1332. http:\/\/dx.doi.org\/10.1016\/j.jhep.2020.06.025<\/li>\n
    15. Hepatol J. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. 2016;64:1388\u2013402.<\/li>\n
    16. Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, Suri D, Thorburn D, Sennett K, Morgan S, Tsochatzis E, Rosenberg W. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. Journal of Hepatology. 2019;71(2):371-378. http:\/\/dx.doi.org\/10.1016\/j.jhep.2019.03.033<\/li>\n
    17. Harrison S, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik F, Darteil R, Liebe R, Magnanensi J, Hajji Y, Brozek J, Roudot A, Staels B, Hum D, Megnien S, Hosmane S, Dam N, Chaumat P, Hanf R, Anstee Q, Sanyal A. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology &amp; Hepatology. 2020;5(11):970-985. http:\/\/dx.doi.org\/10.1016\/s2468-1253(20)30252-1<\/li>\n
    18. Liang Y, Li D. Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy. BMC Gastroenterology. 2020;20(1):. http:\/\/dx.doi.org\/10.1186\/s12876-020-01234-x<\/li>\n
    19. Dennis A, Kelly M, Fernandes C, Mouchti S, Fallowfield J, Hirschfield G, Pavlides M, Harrison S, Chakravarthy M, Banerjee R, Sanyal A. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. Frontiers in Endocrinology. 2021;11:. http:\/\/dx.doi.org\/10.3389\/fendo.2020.575843<\/li>\n
    20. Francque S, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus J, Zelber-Sagi S, Hallsworth K, Busetto L, Fr\u00fchbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek G, Vinker S, Ungan M, Mendive J, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports. 2021;3(5):100322. http:\/\/dx.doi.org\/10.1016\/j.jhepr.2021.100322<\/li>\n
    21. Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. Journal of Hepatology. 2017;67(4):829-846. http:\/\/dx.doi.org\/10.1016\/j.jhep.2017.05.016<\/li>\n
    22. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman S, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367-378.e5. http:\/\/dx.doi.org\/10.1053\/j.gastro.2015.04.005<\/li>\n
    23. Houttu V, Csader S, Nieuwdorp M, Holleboom A, Schwab U. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Frontiers in Nutrition. 2021;8:. http:\/\/dx.doi.org\/10.3389\/fnut.2021.716783<\/li>\n
    24. Karam G, Agarwal A, Sadeghirad B, Jalink M, Hitchcock C, Ge L, Kiflen R, Ahmed W, Zea A, Milenkovic J, Chedrawe M, Rabassa M, El Dib R, Goldenberg J, Guyatt G, Boyce E, Johnston B. Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis. BMJ. 2023;:e072003. http:\/\/dx.doi.org\/10.1136\/bmj-2022-072003<\/li>\n
    25. Chiu S, Sievenpiper J, de Souza R, Cozma A, Mirrahimi A, Carleton A, Ha V, Di Buono M, Jenkins A, Leiter L, Wolever T, Don-Wauchope A, Beyene J, Kendall C, Jenkins D. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. European Journal of Clinical Nutrition. 2014;68(4):416-423. http:\/\/dx.doi.org\/10.1038\/ejcn.2014.8<\/li>\n
    26. Shepherd E, Saborano R, Northall E, Matsuda K, Ogino H, Yashiro H, Pickens J, Feaver R, Cole B, Hoang S, Lawson M, Olson M, Figler R, Reardon J, Nishigaki N, Wamhoff B, G\u00fcnther U, Hirschfield G, Erion D, Lalor P. Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. JHEP Reports. 2021;3(2):100217. http:\/\/dx.doi.org\/10.1016\/j.jhepr.2020.100217<\/li>\n
    27. Orci L, Gariani K, Oldani G, Delaune V, Morel P, Toso C. Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression. Clinical Gastroenterology and Hepatology. 2016;14(10):1398-1411. http:\/\/dx.doi.org\/10.1016\/j.cgh.2016.04.036<\/li>\n
    28. Lassailly G, Caiazzo R, Ntandja-Wandji L, Gnemmi V, Baud G, Verkindt H, Ningarhari M, Louvet A, Leteurtre E, Raverdy V, Dharancy S, Pattou F, Mathurin P. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020;159(4):1290-1301.e5. http:\/\/dx.doi.org\/10.1053\/j.gastro.2020.06.006<\/li>\n
    29. Moolla A, Motohashi K, Marjot T, Shard A, Ainsworth M, Gray A, Holman R, Pavlides M, Ryan J, Tomlinson J, Cobbold J. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterology. 2019;10(4):337-346. http:\/\/dx.doi.org\/10.1136\/flgastro-2018-101155<\/li>\n
    30. Francque S, Bedossa P, Ratziu V, Anstee Q, Bugianesi E, Sanyal A, Loomba R, Harrison S, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg J, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-G\u00f3mez M, Huot-Marchand P, Baudin M, Richard M, Abitbol J, Broqua P, Junien J, Abdelmalek M. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. New England Journal of Medicine. 2021;385(17):1547-1558. http:\/\/dx.doi.org\/10.1056\/nejmoa2036205<\/li>\n
    31. Sanyal A, Chalasani N, Kowdley K, McCullough A, Diehl A, Bass N, Neuschwander-Tetri B, Lavine J, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt E, Kleiner D, Hoofnagle J, Robuck P. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2010;362(18):1675-1685. http:\/\/dx.doi.org\/10.1056\/nejmoa0907929<\/li>\n
    32. Han M, Altayar O, Hamdeh S, Takyar V, Rotman Y, Etzion O, Lefebvre E, Safadi R, Ratziu V, Prokop L, Murad M, Noureddin M. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2019;17(4):616-629.e26. http:\/\/dx.doi.org\/10.1016\/j.cgh.2018.06.011<\/li>\n
    33. Younossi ZM, Ratziu V, Loomba R. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019;394:2184\u201396.<\/li>\n
    34. Harrison S, Bashir M, Guy C, Zhou R, Moylan C, Frias J, Alkhouri N, Bansal M, Baum S, Neuschwander-Tetri B, Taub R, Moussa S. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2019;394(10213):2012-2024. http:\/\/dx.doi.org\/10.1016\/s0140-6736(19)32517-6<\/li>\n
    35. Newsome P, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal A, Sejling A, Harrison S. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2021;384(12):1113-1124. http:\/\/dx.doi.org\/10.1056\/nejmoa2028395<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Prof. Sergienko O.I., prof. Oparin A.G., assoc. prof. Novokhatnya \u0410.E. \u00a0 Kharkiv National Medical University Department of therapy \u21162 Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of liver diseases: 25% of the population of European countries have signs of NAFLD, 10\u201320% of patients with steatosis develop an inflammatory process (non-alcoholic…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,108,101,107,89],"tags":[],"translation":{"provider":"WPGlobus","version":"2.12.2","language":"en","enabled_languages":["uk","en","ru"],"languages":{"uk":{"title":true,"content":true,"excerpt":false},"en":{"title":true,"content":true,"excerpt":false},"ru":{"title":false,"content":false,"excerpt":false}}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/3548"}],"collection":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/comments?post=3548"}],"version-history":[{"count":7,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/3548\/revisions"}],"predecessor-version":[{"id":3737,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/3548\/revisions\/3737"}],"wp:attachment":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/media?parent=3548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/categories?post=3548"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/tags?post=3548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}